Aurora Spine Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA05206X1087
CAD
0.27
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Aurora Spine Corp. stock-summary
stock-summary
Aurora Spine Corp.
Pharmaceuticals & Biotechnology
Aurora Spine Corporation is a Canada-based holding company. The Company's segment includes its focus on the development and sale of minimally invasive, interspinous fusion systems and devices. The Company's interspinous process (ISP) lumbar fusion devices include the ZIP and ZIP ULTRA, the ZIP LP and the ZIP-51. In addition, the Company offers a line of interbody products, such as the TiNano product line, including EOS, Echo and EchoXL for the lumbar section of the spine, and discovery for cervical procedures. Its product lines include ISP lumbar fusion devices; polyether ether ketone (PEEK) interbody cages, and Stand-alone (SA) Cervical and Lumbar devices. Its interbody cage products are used to fill the space between vertebrae after degenerative disc material has been removed. Its VOX is a minimally invasive lateral lumbar interbody fusion (LLIF) system featuring TiNano titanium spray coating technology. It characterizes business in the United States and outside the United States.
Company Coordinates stock-summary
Company Details
20 HOLLY STREET, SUITE 300 , TORONTO ON : M4S 3B1
stock-summary
Tel: 1 760 4242004
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Trent Northcutt
President, Chief Executive Officer, Director
Tracy Graf
Independent Director
Mr. J. Daryl MacLellan
Independent Director
Mr. David Rosenkrantz
Independent Director
Mr. Michael Seid
Independent Director
Mr. James Snow
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 24 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.34

stock-summary
Return on Equity

-24.01%

stock-summary
Price to Book

4.37